Hep B Cure May Lie In Reducing Surface Antigen

Among the topics at the European liver meeting was whether reducing HBV surface antigen might be part of a combination approach to curing chronic hepatitis B. One of the leaders in this approach, Arbutus, is working toward its own internal combo therapy for the virus.

More from Anti-infective

More from Therapy Areas